Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26012973 | 1.00 | GBA1 (0.47) | GBA1PDCD1CD274HRH3HRH2 | |
| SCHEMBL17574694 | 1.00 | GBA1 (0.47) | GBA1PDCD1CD274HRH3HRH2 | |
| SCHEMBL24428913 | 0.94 | GBA1 (0.42) | GBA1PDCD1CD274HRH3HRH2 | |
| SCHEMBL11932479 | 0.90 | GBA1 (0.49) | GBA1HRH3HRH2HRH1KCNA3 | |
| SCHEMBL7375999 | 0.89 | HTR1A (0.49) | GBA1PDCD1CD274HRH3HRH2 | |
| SCHEMBL18233564 | 0.88 | KCNA3 (0.43) | GBA1PDCD1CD274HRH3HRH2 | |
| SCHEMBL8085779 | 0.88 | KCNA3 (0.43) | GBA1PDCD1CD274HRH3HRH2 | |
| SCHEMBL13519663 | 0.88 | KCNA3 (0.43) | GBA1PDCD1CD274HRH3HRH2 | |
| SCHEMBL26013893 | 0.84 | PDCD1 (0.40) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL28960041 | 0.83 | PDCD1 (0.49) | PDCD1CD274HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265092-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265092-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265092-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | POLR2E, POLR2H, POLRMT | GBA1 437/4885PDCD1 1338/4885CD274 3601/4885 |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | GBA1 4224/4885PDCD1 4345/4885CD274 3791/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | GBA1 3512/4885PDCD1 3002/4885CD274 2912/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | GBA1 3158/4885PDCD1 3086/4885CD274 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.